Back to Search Start Over

Liver metastasis affects progression pattern during immune checkpoint inhibitors monotherapy in gastric cancer.

Authors :
Motoo I
Ando T
Hamashima T
Kajiura S
Sakumura M
Ueda Y
Murayama A
Ogawa K
Tsukada K
Ueda A
Suzuki N
Nakada N
Nakashima K
Hosokawa A
Yasuda I
Source :
Frontiers in oncology [Front Oncol] 2023 Sep 15; Vol. 13, pp. 1193533. Date of Electronic Publication: 2023 Sep 15 (Print Publication: 2023).
Publication Year :
2023

Abstract

Introduction: The efficacy of immune checkpoint inhibitors (ICIs) is heterogeneous at each metastatic site, and tumor progression pattern is associated with survival; however, it remains unclear in gastric cancer (GC). Therefore, we aimed to clarify the progression pattern in response to ICIs in patients with GC, and we analyzed its mechanism focusing on the intratumoral immune cells.<br />Methods: Patients who received ICIs were retrospectively classified into non-systemic and systemic progression groups based on their radiological assessments. Moreover, the best percentage change in target lesions from each organ was compared.<br />Results: Among 148 patients, the non-systemic progression group showed a significant improvement in overall survival (OS) compared with the systemic progression group (median, 5.6 months vs. 3.3 months; HR, 0.53; 95%CI, 0.32-0.89; p = 0.012). Poor performance status (HR, 1.73, 95%CI, 1.00-2.87) and systemic progression (HR, 3.09, 95%CI, 1.95-4.82) were associated with OS. Of all metastatic sites, the liver showed the poorest percentage change, and liver metastasis (OR, 2.99, 95%CI, 1.04-8.58) was associated with systemic progression. Hence, intratumoral CD8+ T-cell density was lower in patients with liver metastasis than in those without liver metastasis after ICIs, although the density of CD4+ T-cells (Th1, Th17, and Treg) and CD163+ cells (TAM) were not significantly different.<br />Conclusion: The new progression pattern was associated with OS in GC. Liver metastasis may be a predictive factor of systemic progression during ICIs by regulating intratumoral CD8+ T-cells.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Motoo, Ando, Hamashima, Kajiura, Sakumura, Ueda, Murayama, Ogawa, Tsukada, Ueda, Suzuki, Nakada, Nakashima, Hosokawa and Yasuda.)

Details

Language :
English
ISSN :
2234-943X
Volume :
13
Database :
MEDLINE
Journal :
Frontiers in oncology
Publication Type :
Academic Journal
Accession number :
37790758
Full Text :
https://doi.org/10.3389/fonc.2023.1193533